EP3154956A4 - Glucagon antagonists - Google Patents

Glucagon antagonists Download PDF

Info

Publication number
EP3154956A4
EP3154956A4 EP20150805822 EP15805822A EP3154956A4 EP 3154956 A4 EP3154956 A4 EP 3154956A4 EP 20150805822 EP20150805822 EP 20150805822 EP 15805822 A EP15805822 A EP 15805822A EP 3154956 A4 EP3154956 A4 EP 3154956A4
Authority
EP
Grant status
Application
Patent type
Prior art keywords
glucagon antagonists
glucagon
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20150805822
Other languages
German (de)
French (fr)
Other versions
EP3154956A1 (en )
Inventor
Lin Zhi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Original Assignee
Ligand Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57Aryl or substituted aryl radicals
EP20150805822 2014-06-12 2015-06-11 Glucagon antagonists Pending EP3154956A4 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US201462011547 true 2014-06-12 2014-06-12
US201462073916 true 2014-10-31 2014-10-31
US201462078926 true 2014-11-12 2014-11-12
PCT/US2015/035400 WO2015191900A1 (en) 2014-06-12 2015-06-11 Glucagon antagonists

Publications (2)

Publication Number Publication Date
EP3154956A1 true EP3154956A1 (en) 2017-04-19
EP3154956A4 true true EP3154956A4 (en) 2018-01-17

Family

ID=54834341

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20150805822 Pending EP3154956A4 (en) 2014-06-12 2015-06-11 Glucagon antagonists

Country Status (3)

Country Link
US (1) US10076504B2 (en)
EP (1) EP3154956A4 (en)
WO (1) WO2015191900A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102292316B (en) 2008-08-13 2015-07-01 症变治疗公司 Glucagon antagonists
EP3154956A4 (en) 2014-06-12 2018-01-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
CN106336387A (en) * 2015-07-10 2017-01-18 浙江海正药业股份有限公司 Amides derivative, preparation method thereof and purpose of amides derivative on medicine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008098244A1 (en) * 2007-02-09 2008-08-14 Metabasis Therapeutics, Inc. Novel antagonists of the glucagon receptor

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3524846A (en) 1967-06-02 1970-08-18 Syntex Corp Process for the didealkylation of phosphonate esters
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US5091552A (en) 1986-06-30 1992-02-25 Board Of Regents, The University Of Texas System Novel antitumor aldophosphamide analogs
JPH0738070B2 (en) 1986-07-25 1995-04-26 富士写真フイルム株式会社 Silver halide photographic light-sensitive material
EP0284240B2 (en) 1987-03-09 1993-06-16 EASTMAN KODAK COMPANY (a New Jersey corporation) Photographic silver halide materials and process comprising a pyrazolotriazole coupler
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
EP0533833B1 (en) 1990-06-13 1995-12-20 GLAZIER, Arnold Phosphorous produgs
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
DE69426904D1 (en) 1993-06-29 2001-04-26 Mitsubishi Chem Corp Phosphonate-nucleotide ester derivatives
US5780058A (en) 1995-07-21 1998-07-14 Alza Corporation Oral delivery of discrete units
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
JPH09241284A (en) 1996-03-08 1997-09-16 Nippon Soda Co Ltd New oxyazaphosphorine derivative
JPH1197740A (en) 1997-09-19 1999-04-09 Showa Denko Kk Epitaxial wafer for gap light emitting diode and gap light emitting diode
DE69807748T2 (en) 1997-12-22 2003-01-02 Alza Corp Membranes for controlling the flow in devices controlled release
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
WO2000025753A3 (en) 1998-11-02 2000-08-31 Alza Corp Controlled delivery of active agents
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
ES2250128T3 (en) 1999-05-17 2006-04-16 Agouron Pharmaceuticals, Inc. Antagonists / inverse agonists of glucagon.
WO2000071510A3 (en) 1999-05-24 2001-08-30 Cor Therapeutics Inc INHIBITORS OF FACTOR Xa
WO2001019830A1 (en) 1999-09-10 2001-03-22 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
DE10008329A1 (en) 2000-02-23 2001-08-30 Merck Patent Gmbh New aminosulfonyl-biphenyl derivatives are Factor Xa and Factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, arteriosclerosis, inflammation or angina pectoris
JP2004501897A (en) 2000-06-23 2004-01-22 ノボ ノルディスク アクティーゼルスカブNovo Nordisk Aktie Selsxab Glucagon antagonists / inverse agonists
WO2002040444A1 (en) 2000-11-17 2002-05-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
US20030212119A1 (en) 2001-12-20 2003-11-13 Jesper Lau Novel glucagon receptor antagonists/inverse agonists
WO2003053938A1 (en) 2001-12-20 2003-07-03 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
US20040152750A1 (en) 2002-12-20 2004-08-05 Kodra Janos Tibor Novel glucagon antagonists
US7138529B2 (en) 2003-04-16 2006-11-21 Hoffmann-La Roche Inc. Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
EP1689383B1 (en) 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
EP1690538A4 (en) 2003-12-02 2009-02-25 Shionogi & Co Isoxazole derivative having agonistic activity against peroxisome proliferator-activated receptor
JP2007514794A (en) 2003-12-19 2007-06-07 メルク エンド カムパニー インコーポレーテッドMerck & Company Incoporated Cyclic guanidines, compositions comprising such compounds, and methods of use
US20070015757A1 (en) 2003-12-19 2007-01-18 Novo Nordisk A/S Novel Glucagon Antagonists/Inverse Agonists
EP1758859B1 (en) 2004-05-28 2013-07-17 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
DE602005006806D1 (en) 2004-06-04 2008-06-26 Merck & Co Inc Pyrazole derivatives, compositions containing such compounds, and application procedures
WO2005123668A1 (en) 2004-06-14 2005-12-29 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
US7687665B2 (en) 2004-06-24 2010-03-30 Incyte Corporation 2-methylprop anamides and their use as pharmaceuticals
DE602005017895D1 (en) 2004-07-07 2010-01-07 Merck & Co Inc Pyrazolamid derivatives, these compositions and application process connections containing
EP1773330B1 (en) 2004-07-22 2010-05-26 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
CA2597073C (en) 2005-02-11 2014-11-25 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
JP2008533200A (en) 2005-03-21 2008-08-21 メルク エンド カムパニー インコーポレーテッドMerck & Company Incoporated Compositions and usage containing substituted aryl and heteroaryl derivatives, such compounds
CA2614537A1 (en) 2005-07-26 2007-02-08 Merck & Co., Inc. Process for synthesizing a substituted pyrazole
DK1951661T3 (en) 2005-11-17 2012-09-03 Lilly Co Eli Glucagon receptor antagonists, the preparation and therapeutic uses thereof
EP1951658B1 (en) 2005-11-17 2012-09-26 Eli Lilly & Company Glucagon receptor antagonists, preparation and therapeutic uses
ES2516691T3 (en) 2005-11-22 2014-10-31 Eli Lilly & Company Glucagon receptor antagonists, preparation and therapeutic uses
US7807702B2 (en) 2005-11-23 2010-10-05 Eli Lilly And Company Substituted thiophene carboxylic amide glucagon receptor antagonists, preparation and therapeutic uses
EP2001472A2 (en) 2006-03-23 2008-12-17 Merck and Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2009537525A (en) 2006-05-16 2009-10-29 メルク エンド カムパニー インコーポレーテッドMerck & Company Incoporated Glucagon receptor antagonist compounds, compositions and methods of use comprising such compounds
WO2008001883A1 (en) 2006-06-29 2008-01-03 Nissan Chemical Industries, Ltd. α-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT
CN102292316B (en) 2008-08-13 2015-07-01 症变治疗公司 Glucagon antagonists
EP2734207A4 (en) 2011-07-18 2015-06-17 Tokai Pharmaceuticals Inc Novel compositions and methods for treating prostate cancer
EP3154956A4 (en) 2014-06-12 2018-01-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
CN106687118A (en) 2014-07-02 2017-05-17 配体药物公司 Prodrug compounds and uses thereof
JP2017051900A (en) 2015-09-08 2017-03-16 国立大学法人横浜国立大学 Catalyst, and production method thereof
CN205117265U (en) 2015-11-19 2016-03-30 北京美高科技发展有限公司 Cable formula electrohydraulic control cuts piping tool

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008098244A1 (en) * 2007-02-09 2008-08-14 Metabasis Therapeutics, Inc. Novel antagonists of the glucagon receptor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ERIC G. VAJDA ET AL: "Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus", DIABETES, OBESITY AND METABOLISM, vol. 19, no. 1, 31 August 2016 (2016-08-31), pages 24 - 32, XP055433574, ISSN: 1462-8902, DOI: 10.1111/dom.12752 *
SAN DIEGO: "Ligand Initiates Phase 1 Trial with Glucagon Receptor Antagonist for Type 2 Diabetes", DIABETES WEEK, 25 November 2013 (2013-11-25), pages 90, XP055433861, Retrieved from the Internet <URL:https://content.equisolve.net/ligand/news/2013-11-12_Ligand_Initiates_Phase_1_Trial_with_Glucagon_198.pdf> *
See also references of WO2015191900A1 *

Also Published As

Publication number Publication date Type
US20170216229A1 (en) 2017-08-03 application
JP2017519000A (en) 2017-07-13 application
US10076504B2 (en) 2018-09-18 grant
WO2015191900A1 (en) 2015-12-17 application
EP3154956A1 (en) 2017-04-19 application

Legal Events

Date Code Title Description
AK Designated contracting states:

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AV Request for validation of the european patent in

Extension state: MA

AX Request for extension of the european patent to

Extension state: BA ME

17P Request for examination filed

Effective date: 20170111

DAV Request for validation of the european patent (in any country) deleted
DAX Request for extension of the european patent (to any country) deleted
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1231053

Country of ref document: HK

A4 Despatch of supplementary search report

Effective date: 20171220

RIC1 Classification (correction)

Ipc: A61K 31/167 20060101ALI20171214BHEP

Ipc: A61P 3/10 20060101ALI20171214BHEP

Ipc: C07C 309/15 20060101ALI20171214BHEP

Ipc: A61K 31/423 20060101ALI20171214BHEP

Ipc: C07D 307/81 20060101AFI20171214BHEP